Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002375 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
A NA study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00002375 is a NA study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants.
The verdict
NCT00002375, a NA study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications. It is thought that IDV plus NFV will be a safe drug combination for treating HIV.
Interventions
- DRUG Indinavir sulfate
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002375
The ClinicalTrials.gov registry entry for NCT00002375 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002375 about?
NCT00002375 is a clinical study titled "Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications. It is thought that IDV plus NFV will be a safe drug combination for treating HIV.
What is the current status of trial NCT00002375?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants.
What interventions are being tested in trial NCT00002375?
The interventions under investigation include: Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002375?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.